Latest News and Press Releases

U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and...

– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing...

Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna...

Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across...

– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 ...

– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...

– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE...

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...